Medicare Enrolled
Dr. Vir Nanda, MD
Internal Medicine · Victorville, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Mixed engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Nanda from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Nanda?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Nanda
Dr. Vir Nanda is an internal medicine specialist in Victorville, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Nanda performed 17,957 Medicare services across 1,516 unique beneficiaries.
Between the years covered by Open Payments, Dr. Nanda received a total of $16,029 from 63 pharmaceutical and/or device companies across 503 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Nanda is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 1% volume in CA
$16,029 industry payments
Medicare Practice Summary
Medicare Utilization ↗17,957
Medicare services
Top 1% in CA for internal medicine
1,516
Unique beneficiaries
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~998 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (aprepitant) | 4,550 | $1 | $10 |
| Denosumab injection (Prolia/Xgeva) | 3,800 | $18 | $61 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,376 | $0 | $2 |
| Anti-nausea injection (ondansetron/Zofran) | 1,960 | $0 | $2 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,020 | $1 | $53 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,013 | $69 | $272 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
395 | $24 | $127 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
326 | $11 | $87 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
288 | $107 | $562 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
276 | $6 | $365 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
273 | $1 | $3 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
228 | $23 | $123 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
178 | $0 | $54 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
157 | $49 | $315 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 149 | $136 | $1,133 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
148 | $95 | $400 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
112 | $19 | $116 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
100 | $27 | $131 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
95 | $1 | $9 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
93 | $104 | $638 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
83 | $53 | $256 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
79 | $131 | $578 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
69 | $13 | $81 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
56 | $1 | $18 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
33 | $136 | $948 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
30 | $40 | $231 |
| New patient office visit, complex (60-74 min) | 19 | $175 | $678 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
18 | $64 | $398 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
18 | $70 | $154 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
15 | $96 | $388 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
5.5% high complexity
83.9% medium
10.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$16,029
Total received (2018-2024)
Avg $2,290/year across 7 years
Top 7% in CA for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
63
Companies
503
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,882 (42.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$5,232 (32.6%)
Other
Charitable contributions, space rental, and other categories
$2,517 (15.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,398 (8.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$8,104
2023
$2,791
2022
$1,558
2021
$1,053
2020
$418
2019
$624
2018
$1,481
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Gilead Sciences, Inc.
$5,232
Novartis Pharmaceuticals Corporation
$1,354
Janssen Biotech, Inc.
$242
Celgene Corporation
$178
JAZZ PHARMACEUTICALS INC.
$123
E.R. Squibb & Sons, L.L.C.
$95
PFIZER INC.
$91
BeiGene USA, Inc.
$75
Astellas Pharma US Inc
$71
Daiichi Sankyo Inc.
$63
AstraZeneca Pharmaceuticals LP
$53
Alexion Pharmaceuticals, Inc.
$50
Bayer Healthcare Pharmaceuticals Inc.
$46
ACCORD HEALTHCARE, INC.
$44
Sumitomo Pharma America, Inc.
$38
Telix Pharmaceuticals
$38
ABBVIE INC.
$33
SpringWorks Therapeutics, Inc.
$33
EMD Serono, Inc.
$32
Incyte Corporation
$31
Merck Sharp & Dohme LLC
$24
PUMA BIOTECHNOLOGY, INC.
$24
ARRAY BIOPHARMA INC
$23
Janssen Pharmaceuticals, Inc
$22
Medtronic, Inc.
$19
Genentech USA, Inc.
$19
SOBI, INC
$18
Eisai Inc.
$18
Agios Pharmaceuticals, Inc.
$15
Top 3 companies account for 84.3% of 2024 payments
All-time payments by company (2018-2024) ›
Gilead Sciences, Inc.
$5,840
Novartis Pharmaceuticals Corporation
$2,671
Janssen Biotech, Inc.
$997
E.R. Squibb & Sons, L.L.C.
$732
Astellas Pharma US Inc
$478
PFIZER INC.
$466
Takeda Pharmaceuticals U.S.A., Inc.
$364
Celgene Corporation
$343
Amgen Inc.
$318
GlaxoSmithKline, LLC.
$277
NOVARTIS PHARMACEUTICALS CORPORATION
$250
Incyte Corporation
$232
AstraZeneca Pharmaceuticals LP
$205
BeiGene USA, Inc.
$201
Kite Pharma, Inc.
$182
Dendreon Pharmaceuticals LLC
$168
Myovant Sciences Inc.
$150
Puma Biotechnology, Inc.
$135
JAZZ PHARMACEUTICALS INC.
$123
Genentech USA, Inc.
$118
Sumitomo Pharma America, Inc.
$116
Daiichi Sankyo Inc.
$106
Seagen Inc.
$101
Alexion Pharmaceuticals, Inc.
$99
Merck Sharp & Dohme Corporation
$87
Regeneron Healthcare Solutions, Inc.
$72
Boehringer Ingelheim Pharmaceuticals, Inc.
$72
PUMA BIOTECHNOLOGY, INC.
$71
Merck Sharp & Dohme LLC
$67
ARRAY BIOPHARMA INC
$58
Eisai Inc.
$55
Karyopharm Therapeutics Inc.
$54
EISAI INC.
$51
Pharmacyclics LLC, An AbbVie Company
$47
Bayer Healthcare Pharmaceuticals Inc.
$46
ACCORD HEALTHCARE, INC.
$44
Janssen Scientific Affairs, LLC
$38
Telix Pharmaceuticals
$38
Teva Pharmaceuticals USA, Inc.
$37
ABBVIE INC.
$33
SpringWorks Therapeutics, Inc.
$33
EMD Serono, Inc.
$32
Rigel Pharmaceuticals, Inc.
$31
Pharmacosmos Therapeutics Inc.
$29
Spectrum Pharmaceuticals Inc.
$24
Medtronic USA, Inc.
$23
Progenics Pharmaceuticals, Inc.
$22
CTI BioPharma Corp.
$22
Janssen Pharmaceuticals, Inc
$22
TOLMAR Pharmaceuticals, Inc.
$21
Coherus Biosciences Inc.
$21
Deciphera Pharmaceuticals Inc.
$21
Medtronic, Inc.
$19
GENZYME CORPORATION
$19
Foundation Medicine, Inc.
$19
Global Blood Therapeutics, Inc.
$18
SOBI, INC
$18
Myriad Genetic Laboratories, Inc.
$17
Bayer HealthCare Pharmaceuticals Inc.
$17
Immunomedics, Inc.
$16
Agios Pharmaceuticals, Inc.
$15
INSYS Therapeutics Inc
$14
Taiho Oncology, Inc.
$13
Top 3 companies account for 59.3% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · Avastin · BAVENCIO · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Blincyto · CALQUENCE · CAMCEVI · DARZALEX · DOPTELET · ELIGARD · ELIQUIS · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · Enhertu · Erleada · FOUNDATIONONE · Fabhalta · Folotyn · GILOTRIF · Herceptin · IBRANCE · ICLUSIG · ILLUCCIX · IMBRUVICA · IMFINZI · INLYTA · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KYPHON Balloon Kyphoplasty · KYPHON EXPRESS II KYPHOPAK TRAY · Kyprolis · LIBTAYO · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · MYRISK · NERLYNX · NINLARO · Nerlynx · Nplate · Nubeqa · OGSIVEO · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Ocrevus · PADCEV · PIQRAY · PROMACTA · PROVENGE · PYLARIFY · PYRUKYND · Perjeta · Pomalyst · QINLOCK · REBLOZYL · RYBREVANT · RYDAPT · RYLAZE · Revlimid · SCEMBLIX · SUTENT · SYNDROS · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TECVAYLI · TUKYSA · Tavalisse · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VELCADE · VENCLEXTA · VYNDAQEL · Vonjo · Vyloy · XALKORI · XPOVIO · XTANDI · Xospata · Xtandi · Yescarta · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (43%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 7% for internal medicine in CA.
Geographic Context
Internal medicine physicians within 10 mi
123
Per 100K population
5.6
County median income
$82,184
Nearest hospital
VICTOR VALLEY GLOBAL MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Nanda is a mixed practice specialist, with above-average Medicare volume (top 1% in CA), with mixed engagement industry engagement in the top 7% of CA peers, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Nanda experienced with anti-nausea injection (aprepitant)?
Based on Medicare claims data, Dr. Nanda performed 4,550 anti-nausea injection (aprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Nanda receive payments from pharmaceutical companies?
Yes. Dr. Nanda received a total of $16,029 from 63 companies across 503 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Nanda's costs compare to other internal medicine physicians in Victorville?
Dr. Nanda's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Nanda) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Victorville
Browse internal medicine physicians in Victorville ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in CA
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in CA
Which CA internal medicine physicians receive the most from drug and device companies.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology